DaVita (DVA) Set to Post Quarterly Earnings on Thursday

DaVita (NYSE:DVA) is anticipated to announce its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect DaVita to post earnings of $3.57 per share and revenue of $3.52 billion for the quarter. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same period last year, the company earned $2.95 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. On average, analysts expect DaVita to post $14.57 EPS for the current fiscal year and $17.25 EPS for the next fiscal year.

DaVita Trading Up 0.3%

DaVita stock opened at $184.66 on Tuesday. DaVita has a 1 year low of $101.00 and a 1 year high of $247.49. The company has a market cap of $11.78 billion, a PE ratio of 15.15, a PEG ratio of 0.48 and a beta of 0.80. The company’s 50-day moving average is $180.60 and its two-hundred day moving average is $174.99.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on DVA shares. Barclays boosted their price target on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 price objective on shares of DaVita in a research note on Wednesday, August 5th. Oppenheimer set a $220.00 target price on shares of DaVita in a report on Friday, August 7th. Zacks Research cut shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $233.43.

About DaVita

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.